en
1726-7536
1735-8507
69
2139
288
gregorian
2015
3
10
16
2
online
1
fulltext
en
25927026
Effect of Administration of Single Dose GnRH Agonist in Luteal Phase on Outcome of ICSI-ET Cycles in Women with Previous History of IVF/ICSI Failure: A Randomized Controlled Trial
<p>Background: GnRH agonist administration in the luteal phase has been suggested to beneficially affect the outcome of intracytoplasmic sperm injection (ICSI) and embryo transfer (ET) cycles. This blind randomized controlled study evaluates the effect of GnRH (Gonadotropine Releasing Hormone) agonist administration on ICSI outcome in GnRH antagonist ovarian stimulation protocol in women with 2 or more previous IVF/ICSI-ET failures.<br />
Methods: One hundred IVF failure women who underwent ICSI cycles and stimulated with GnRH antagonist ovarian stimulation protocol, were included in the study. Women were randomly assigned to intervention (received a single dose injection of GnRH agonist (0.1 mg of Decapeptil) subcutaneously 6 days after oocyte retrieval) and control (did not receive GnRH agonist) groups. Implantation and clinical pregnancy rates were the primary outcome measures.<br />
Results: Although the age of women, the number of embryos transferred in the current cycle and the quality of the transferred embryos were similar in the two groups, there was a significantly higher rate of implantation (Mann Whitney test, p=0.041) and pregnancy (32.6% vs. 12.5%, p=0.030, OR=3.3, 95%CI, 1.08 to 10.4) in the intervention group.<br />
Conclusion: Our results suggested that, in addition to routine luteal phase support using progesterone, administration of 0.1 mg of Decapeptil 6 days after oocyte retrieval in women with previous history of 2 or more IVF/ICSI failures led to a significant improvement in implantation and pregnancy rates after ICSI following ovarian stimulation with GnRH antagonist protocol.</p>
Decapeptil, GnRH agonist, GnRH antagonist, ICSI, Implantation failure, Intracytoplasmic sperm injection, IVF failure, Luteal phase support
096
102
https://www.jri.ir/article/641
https://www.jri.ir/documents/fullpaper/en/641.pdf
SiminZafardoustReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran1405
MahmoodJeddi-TehraniReproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iranمحمود جدیتهرانی54
Mohammad MehdiAkhondiReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iranمحمدمهدیآخوندی21
Mohammad RezaSadeghiReproductive Immunology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran محمدرضاصادقی77
KooroshKamaliReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran1427
SaraMokhtarReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran1406
BitaBadehnooshReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran1407
FarnazFatemiReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iranفرنازفاطمي814
AfsanehMohammadzadehReproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iranافسانهمحمدزادهaf85af@yahoo.com684